Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+0.51%
-3.52%
0.00%
-44.79%
AZN
Astrazeneca
$67.57
Chart
73.5
73.57
65.57
78.54
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.51%
-3.52%
0.00%
-44.79%
AZN
Astrazeneca
$67.57
Chart
73.5
73.57
65.57
78.54
AZN Latest Headlines
AstraZeneca posts positive late-stage data for Imfinzi in bladder cancer.
Fri May 9, 2025
AstraZenecas bladder cancer treatment shows positive results in trial.
Fri May 9, 2025
Tempus AI Strikes $200M Deal With AstraZeneca Pathos To Build Worlds Largest Oncology Model. ) during the first quarter secured a multi-million dollar deal to build “.the world’.s largest foundation model for oncology.”. call on Tuesday Tempus shed light on its new $200 million three-year data and modeling license agreement with ) and “.And this is big for a few reasons”. said Tempus CEO brings the company'.s total remaining contract value to $1 billion and provides
Wed May 7, 2025
AstraZenecas Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma. On Friday ) reported topline data from Phase 3 KALOS and LOGOS trials in patients .KALOS and LOGOS trials assessed the efficacy and safety of Breztri Aerosphere(budesonide/glycopyrronium/formoterol fumarate or BGF) compared with two fixed-dose dual-combination therapies of budesonid (an ICS) and formoterol fumarate (LABA) andSymbicortpressurized metered-dose inhaler (pMDI).KALOS and LOGOS includ
Fri May 2, 2025
AstraZeneca succeeds in late-stage trials for asthma therapy.
Fri May 2, 2025
AstraZenecas New Asthma Treatment Shows Strong Results In Late-stage Trials . (RTTNews) - AstraZeneca Plc.s (AZN.L AZN) triple-combination inhaler Breztri Aerosphere has shown positive results in late-stage clinical trials for patients with uncontrolled asthma. The trials called KALOS and LOGOS found that the inhaler significantly improved lung funct
Fri May 2, 2025
What Does the Market Think About AstraZeneca?. ) short percent of float has fallen 41.18% since its last report. The company recently reported that it has Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will fall. Traders make money from short selling if the price ...
Tue Apr 29, 2025
AstraZeneca Tops Earnings Views And Shares Rise Despite Cancer Miss. AstraZeneca stock rose moderately Tuesday despite a mixed first-quarter report and a setback for its experimental prostate cancer treatment.The post AstraZeneca Tops Earnings Views And Shares Rise Despite Cancer Miss appeared first on Investor'.s Business Daily.
Tue Apr 29, 2025
AstraZeneca warns of potential additional tax penalties in China.
Tue Apr 29, 2025
AstraZeneca discontinues Truqap trial in castration-resistant prostate cancer.
Tue Apr 29, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Login to display Astrazeneca (AZN) recommendation from the last 90 days from financial news and social media.
Hover over the category for more information
